ABOUT LINK ALTERNATIF MBL77

Apart from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and fit enough to tolerate FCR therapy, should be very good candidates to the latter, With all the benefit being this treatment method could be completed in six months even though ibrutinib should be taken indefinitely. This selection might be specifically valuable for non-compli